CORT125329
/ Corcept Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 17, 2025
The Selective Glucocorticoid Receptor Modulator Cort125329 Decreases Neuroinflammation and Gliosis and Enhances Myelination in the Wobbler Model of Amyotrophic Lateral Sclerosis.
(PubMed, Mol Neurobiol)
- "The beneficial effects of CORT125329 correlated with enhanced motor behavioral performance and trophic changes of the forelimbs. In conclusion, our results support further preclinical and clinical studies on GR modulators in sporadic amyotrophic lateral sclerosis."
IO biomarker • Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Oncology • Solid Tumor • BDNF • CHAT • HMGB1 • TLR4 • TNFA
February 09, 2022
Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=115 | Completed | Sponsor: Corcept Therapeutics | Recruiting ➔ Completed
Trial completion
November 08, 2021
Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants
(clinicaltrials.gov)
- P1; N=106; Recruiting; Sponsor: Corcept Therapeutics; Trial completion date: Sep 2021 ➔ Feb 2022; Trial primary completion date: Jul 2021 ➔ Dec 2021
Clinical • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1